OncoMatch

OncoMatch/Clinical Trials/NCT06472388

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Is NCT06472388 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Everolimus 5 MG for neuroendocrine tumors.

Phase 2RecruitingAC Camargo Cancer CenterNCT06472388Data as of Jun 2026Location: Brazil

Treatment: Everolimus 5 MGEverolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different types of NET. However, it is can cause severe adverse effects. Phase I trial demonstrated that a dose of 5mg/day/week was sufficient to inhibit cell proliferation by blocking the mTOR pathway. This is a randomized, open-label, phase II near-equivalence clinical trial of oral everolimus 5 mg vs 10 mg oral/daily and continuously in patients with Grade 1 or Grade 2 metastatic NET, with tumor progression or intolerance to at least one line of treatment and with radiological disease progression within 6 months.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Everolimus 5 MG

Cancer type

Neuroendocrine Tumor

Pancreatic Cancer

Disease stage

Grade: 12

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≥ 16

Prior therapy

Min 1 prior line

Must have received:

At least one previous line of systemic treatment (suspended for more than 3 weeks).

Lab requirements

Blood counts

hemoglobin > 8 g/dl; neutrophils ≥ 1,500/mm³; platelets > 90,000/mm³

Kidney function

creatinine < 1.5 mg/dl

Liver function

ast and alt ≤ 2.5 x uln or ≤ 5 x uln for patients with liver metastases; bilirubin ≤ 1.5 x uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06472388 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received .

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify